EUVIMEDEUVIMED entdecken
Open Access

Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care

Andrea Vingiani iD, Luca Agnelli iD, Matteo Duca iD, Daniele Lorenzini iD, Silvia Damian iD, Claudia Proto, Monica Niger iD, Federico Nichetti iD, Elena Tamborini iD, Federica Perrone, Alberta Piccolo iD, Siranoush Manoukian iD und 21 weitere

JCO Precision Oncology · 2023

DOI: 10.1200/po.23.00067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Andrea Vingiani und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The investigation of multiple molecular targets with next-generation sequencing (NGS) has entered clinical practice in oncology, yielding to a paradigm shift from the histology-centric approach to the mutational model for personalized treatment. Accordingly, most of the drugs recently approved in oncology are coupled to specific biomarkers. One potential tool for implementing the mutational model of precision oncology in daily practice is represented by the Molecular Tumor Board (MTB), a multidisciplinary team whereby molecular pathologists, biologists, bioinformaticians, geneticists, medical oncologists, and pharmacists cooperate to generate, interpret, and match molecular data with personalized treatments. PATIENTS AND METHODS Since May 2020, the institutional MTB set at Fondazione IRCCS Istituto Nazionale Tumori of Milan met weekly via teleconference to discuss molecular data and potential therapeutic options for patients with advanced/metastatic solid tumors. RESULTS Up to October 2021, among 1,996 patients evaluated, we identified >10,000 variants, 43.2% of which were functionally relevant (pathogenic or likely pathogenic). On the basis of functionally relevant variants, 711 patients (35.6%) were potentially eligible to targeted therapy according to European Society of Medical Oncology Scale for Clinical Actionability of Molecular Targets tiers, and 9.4% received a personalized treatment. Overall, larger NGS panels (containing >50 genes) significantly outperformed small panels (up to 50 genes) in detecting actionable gene targets across different tumor types. CONCLUSION Our real-world data provide evidence that MTB is a valuable tool for matching NGS data with targeted treatments, eventually implementing precision oncology in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansPrecision MedicinePatient CareMedical OncologyHigh-Throughput Nucleotide Sequencing

Autor:innen und Institutionen

  • Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
  • Computational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
  • Gynecologic Oncology, Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

ORCID-Profile: Andrea Vingiani, Luca Agnelli, Matteo Duca, Daniele Lorenzini, Silvia Damian, Monica Niger, Federico Nichetti, Elena Tamborini, Alberta Piccolo, Siranoush Manoukian, Marta Brambilla, Elena Colombo, Claudio Vernieri, Francesca Marra, Elena Conca, Adele Busico, Fabio Bozzi, Andrea Devecchi, Anna Baggi, Claudio Jommi, Giovanni Apolone, Giancarlo Pruneri

Zitieren

APA

Vingiani, A., Agnelli, L., Duca, M., Lorenzini, D., Damian, S., Proto, C., Niger, M., Nichetti, F., Tamborini, E., Perrone, F., Piccolo, A., Manoukian, S., Azzollini, J., Brambilla, M., Colombo, E., Lopez, S., Vernieri, C., Marra, F., Conca, E., …, & Pruneri, G. (2023). Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care. JCO Precision Oncology. https://doi.org/10.1200/po.23.00067

Vancouver

Vingiani A, Agnelli L, Duca M, Lorenzini D, Damian S, Proto C, et al. Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care. JCO Precision Oncology. 2023. doi:10.1200/po.23.00067

BibTeX
@article{Vingiani2023,
  author = {Vingiani, Andrea and Agnelli, Luca and Duca, Matteo and Lorenzini, Daniele and Damian, Silvia and Proto, Claudia and Niger, Monica and Nichetti, Federico and Tamborini, Elena and Perrone, Federica and Piccolo, Alberta and Manoukian, Siranoush and Azzollini, Jacopo and Brambilla, Marta and Colombo, Elena and Lopez, Salvatore and Vernieri, Claudio and Marra, Francesca and Conca, Elena and Busico, Adele and Capone, Iolanda and Bozzi, Fabio and Angelini, Marta and Devecchi, Andrea and Salvatori, Rebecca and De Micheli, Valentina and Baggi, Anna and Pasini, Silvia and Jommi, Claudio and Ladisa, Vito and Apolone, Giovanni and De Braud, Filippo and Pruneri, Giancarlo},
  title = {Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care},
  journal = {JCO Precision Oncology},
  year = {2023},
  doi = {10.1200/po.23.00067}
}
Kostenlos starten →